Uterine Cervical Dysplasia

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA withdrawal · 2019-04-02
EMA Withdrawn: Silgard (human papillomavirus type 6 L1 protein;human papillomavirus type 11 L1 protein;human papillomavirus type 16 L1 protein;human papillomavirus type 18 L1 protein) — Merck Sharp Dohme Ltd
EMA withdrawn the HPV vaccine Silgard (HPV 6/11/16/18 L1 proteins) from the market.